| W ● BIOSCIENCE . ● Fiscal 2021 3Q Financial Results August 6, 2021 Agenda | --- | --- | --- | |----------------------------------------|-------|-------| | | | | | | | | | Welcome Angela Bitting | | | | SVP, Corporate Affairs | | | | Quarterly Highlights | | | | Emily Leproust | | | | Chief Executive Officer | | | | Financial and Operational Performance | | | | Jim Thorburn | | | | Chief Financial Officer | | | | Pipeline & Milestones | | | | Emily Leproust Chief Executive Officer | | | Q&A Session 2 | TWI ...

Table of Contents FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058888 ...

Twist Bioscience Corp. (NASDAQ:TWST) Q3 2021 Earnings Conference Call August 6, 2021 8:00 AM ET Company Participants Emily Leproust – CEO and Co-Founder Angela Bitting – SVP of Corporate Affairs Jim Thorburn – CFO Conference Call Participants Doug Schenkel – Cowen Matt Sykes – Goldman Sachs Catherine Schulte – Baird Vijay Kumar – Evercore ISI Matt Larew – William Blair (ph) Tycho Peterson – JP Morgan Operator Welcome to Twist Biosciences, Fiscal 2021, Third Quarter Financial results conference call. At this ...

Twist Bioscience Corporation (NASDAQ:TWST) Q2 2021 Results Conference Call May 6, 2021 4:30 PM ET Company Participants Jim Thorburn - Chief Financial Officer Dr. Emily Leproust - CEO and Co-Founder Conference Call Participants Eleni Apostolatos - Cowen Thomas Peterson - Bard Casey Woodring - JPMorgan Vijay Kumar - Evercore Puneet Souda - SVB Leerink Operator Welcome to Twist Bioscience Fiscal 2021 Second Quarter Financial Results Conference Call. At this time, all participants are in a listen-only. After th ...

l W ● BIOSCIENCE . Fiscal 2021 2Q Financial Results May 6, 2021 Agenda | --- | --- | --- | --- | --- | |---------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | Welcome | | | | | | | | | | | | Jim Thorburn Chief Financial Officer | | | | | | Quarterly Highlights | | | | | | Emily Leproust | | | | | | Chief Executive Officer | | | | | | Financial and Operational Performance | | | | | | Jim Thorburn | | | | | | Chief Financial Officer | | | | | | Pipeline & Milestones ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058888 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058 ...

Twist Bioscience Corporation (NASDAQ:TWST) Q1 2021 Earnings Conference Call February 5, 2021 4:30 PM ET Company Participants Jim Thorburn - Chief Financial Officer Emily Leproust - CEO and Co-Founder Conference Call Participants Eleni Apostolatos - JP Morgan Doug Schenkel - Cowen Catherine Schulte - Baird Vijay Kumar - Evercore ISI Puneet Souda - SVB Leerink Operator Welcome to Twist Bioscience's Fiscal 2021 First Quarter Financial Results Conference Call [Operator Instructions]. Please be advised that toda ...

| W ● . ● BIOSCIENCE Fiscal 2021 1Q Financial Results February 4, 2021 Agenda | --- | --- | --- | --- | --- | |----------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | Welcome Jim Thorburn | | | | | | Chief Financial Officer | | | | | | Quarterly Highlights | | | | | | Emily Leproust Chief Executive Officer | | | | | | | | | | | | | | | | | | Financial and Operational Performance | | | | | | Jim Thorburn Chief Financial Officer | | | | | | | ...

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) | Delaware | | 46-20588 ...